Expert testimony exposes COVID-19 vaccine link to blood clots and myocarditis at Senate hearing.
ByAinvest
Monday, Sep 1, 2025 7:48 am ET1min read
MRNA--
Dr. McCullough presented findings from a large autopsy series, stating that in 73.9% of examined post-vaccine deaths, mRNA COVID vaccines were considered the likely cause. This claim sparked intense debate in the medical community. The hearing also highlighted the impact of recent changes in the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC).
The hearing comes amidst a backdrop of significant changes within the CDC. In June, Health and Human Services Secretary Robert F. Kennedy Jr. fired all 17 members of ACIP and replaced them with a new eight-member panel, including several who have openly expressed anti-vaccine sentiments. The newly reconstituted ACIP panel is not scheduled to meet until September 18-19, 2025, and even that meeting is uncertain.
The changes at the CDC have raised concerns about access to vaccines. CVS Pharmacy, a nationwide pharmacy chain, announced it would be unable to offer this season's newly approved COVID-19 vaccine in 16 states and the District of Columbia, where pharmacists are not permitted to administer vaccines not recommended by ACIP. This move could dramatically restrict access to the vaccine in the crucial early weeks of the respiratory virus season.
The hearing also shed light on the potential legal and financial implications for healthcare providers. Physicians could face liability if they do not follow official federal guidance on vaccines. Additionally, the cost for vaccines is already baked into the rates for this current calendar year, but the confusion at the point of service could pose a barrier to access.
In conclusion, the U.S. Senate hearing on COVID-19 vaccine adverse events highlighted the complexities and challenges surrounding the administration and regulation of COVID-19 vaccines. The hearing underscored the need for transparent and evidence-based decision-making in public health.
References:
[1] https://m.economictimes.com/news/international/world-news/blood-clots-surge-like-never-before-mccullough-exposes-mrna-covid-vaccine-lies-at-senate-hearing/amp_podcast/123634833.cms
[2] https://www.pharmacypracticenews.com/Covid-19/Article/08-25/CVS-stops-COVID-shots/78073
The U.S. Senate's Permanent Subcommittee on Investigations held a hearing on COVID-19 vaccine adverse events. Dr. Peter McCullough testified that in 73.9% of examined post-vaccine deaths, mRNA COVID vaccines were the likely cause. The hearing aimed to expose alleged corruption and downplaying of myocarditis and other adverse events associated with COVID-19 vaccines.
The U.S. Senate's Permanent Subcommittee on Investigations held a crucial hearing on July 2, 2025, titled "The Corruption of Science and Federal Health Agencies: How Health Officials Downplayed and Hid Myocarditis and Other Adverse Events Associated with the COVID-19 Vaccines." The hearing aimed to expose alleged corruption and downplaying of adverse events associated with COVID-19 vaccines, including myocarditis. Top medical experts and legal voices testified, including Dr. Peter McCullough, Dr. Jordan Vaughn, Dr. James Thorp, Dr. Joel Wallskog, Attorney Aaron Siri, and Hawaii Governor Josh Green.Dr. McCullough presented findings from a large autopsy series, stating that in 73.9% of examined post-vaccine deaths, mRNA COVID vaccines were considered the likely cause. This claim sparked intense debate in the medical community. The hearing also highlighted the impact of recent changes in the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC).
The hearing comes amidst a backdrop of significant changes within the CDC. In June, Health and Human Services Secretary Robert F. Kennedy Jr. fired all 17 members of ACIP and replaced them with a new eight-member panel, including several who have openly expressed anti-vaccine sentiments. The newly reconstituted ACIP panel is not scheduled to meet until September 18-19, 2025, and even that meeting is uncertain.
The changes at the CDC have raised concerns about access to vaccines. CVS Pharmacy, a nationwide pharmacy chain, announced it would be unable to offer this season's newly approved COVID-19 vaccine in 16 states and the District of Columbia, where pharmacists are not permitted to administer vaccines not recommended by ACIP. This move could dramatically restrict access to the vaccine in the crucial early weeks of the respiratory virus season.
The hearing also shed light on the potential legal and financial implications for healthcare providers. Physicians could face liability if they do not follow official federal guidance on vaccines. Additionally, the cost for vaccines is already baked into the rates for this current calendar year, but the confusion at the point of service could pose a barrier to access.
In conclusion, the U.S. Senate hearing on COVID-19 vaccine adverse events highlighted the complexities and challenges surrounding the administration and regulation of COVID-19 vaccines. The hearing underscored the need for transparent and evidence-based decision-making in public health.
References:
[1] https://m.economictimes.com/news/international/world-news/blood-clots-surge-like-never-before-mccullough-exposes-mrna-covid-vaccine-lies-at-senate-hearing/amp_podcast/123634833.cms
[2] https://www.pharmacypracticenews.com/Covid-19/Article/08-25/CVS-stops-COVID-shots/78073

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet